Gabather enters into a research collaboration with leading US scientists to investigate GT-002 in a unique preclinical model of Alzheimer’s Disease

Gabather AB (Nasdaq First North Growth Market: GABA) today announces the establishment of a research collaboration with Massachusetts General Hospital to investigate the effect of its drug candidate GT-002 in a preclinical model of Alzheimer’s disease. The first stages of the clinical development (single and multiple ascending doses) with GT-002 has recently been successfully completed, paving the way for the development of the drug candidate in a broad range of mental disorders.      

Gabather has signed an agreement with Massachusetts General Hospital, where Dr Kastanenka, Assistant Professor of Neurology at Harvard Medical School, and colleagues will investigate the effects of GT-002 in a preclinical model of Alzheimer's disease. The research will be conducted at Massachusetts General Hospital to elucidate the effects of the drug candidate on sleep-dependent brain rhythms, including slow wave activity. This brain rhythm is important for memory consolidation during sleep and has been shown to be disrupted in Alzheimer’s disease.

“Gabather is excited to enter this very interesting collaboration, exploring the potential effects of GT-002 to not only slow the pathophysiology of Alzheimer’s disease, but also to restore memory and sleep function,” comments Dr Michael-Robin Witt, CEO at Gabather.
In previous preclinical experiments, Gabather’s GABA_A-PAM drug candidate GT-002 has shown marked effects on cognition. The most recent presentation of preclinical data took place at Society for Neuroscience’s Global Connectome, a digital scientific meeting held in January 2021. The poster presentation is available here  

Gabather is continuously striving to expand its intellectual property for GT-002. A second medical use patent application covering GT-002 and related compounds, including a range of new indications such as Alzheimer’s disease and also non-CNS disorders, was filed on 1 March 2021. 

For further information, please contact:

Michael-Robin Witt, CEO
Phone: +46 (0) 73-687 28 39
E-mail: mrw@gabather.comAbout Gabather AB 

Gabather is developing the next generation of therapeutics to treat mental illnesses. The company’s selective GABA_A modulators have a unique mechanism of action that may be fundamental to new and effective drugs for major psychiatric diagnoses. Gabather is currently implementing a clinical development programme for its most advanced clinical drug candidate, GT-002, to improve the treatment of depression. Gabather’s GABA_A modulators may prove to be effective treatments for other diseases that are entirely or partially due to the imbalance within the GABA system, for example, schizophrenia, psychosis, Alzheimer’s disease and autism. Gabather is listed on Nasdaq’s First North Growth Market and Erik Penser Bank (+46 8463 8000, certifiedadviser@penser.se) is the company’s Certified Adviser